1. Pink Sheet

What To Expect As IRA Legal Challenges Mount

US Chamber Of Commerce Suit Raises New Arguments

 
• By Jessica Merrill

Second lawsuit filed against the IRA is not brought by an industry insider, which may reduce the focus on the drug pricing elements of the new Medicare program and highlight the free enterprise principles at stake, potentially putting the case on a more popular footing.

judge gavel
A second lawsuit was filed against the IRA • Source: Shutterstock

Just days after Merck & Co., Inc. filed the first lawsuit against the US government over the implementation of a new Medicare drug price negotiation program ordered under the Inflation Reduction Act (IRA), a second lawsuit was filed by the US Chamber of Commerce.

Key Takeaways
  • The US Chamber of Commerce filed a second lawsuit against the IRA.

“I think we expected a lawsuit from the pharmaceutical industry, which is the most directly impacted by the law, but...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Clinical Trial Diversity Action Plan Guidance Must Return To US FDA Website, Court Says

 
• By Sue Sutter

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.